MLLT3抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07792(MLLT3 Antibody) at dilution 1/155. (Original magnification: ×200)    

  
  

The MLLT3 antibody targets the MLLT3 protein, a key player in transcriptional regulation and chromatin remodeling. Also known as AF9. MLLT3 is encoded by the *MLLT3* gene on human chromosome 9p22 and belongs to the MLLT family of genes involved in chromosomal translocations. Notably, MLLT3 frequently partners with the *MLL* (KMT2A) gene in t(9;11)(p22;q23) translocations, driving aggressive subtypes of acute leukemia, particularly in infants. This fusion generates the MLL-AF9 oncoprotein, which disrupts epigenetic regulation by recruiting DOT1L, a histone methyltransferase, to aberrantly activate HOX gene clusters and sustain leukemic stem cells.

MLLT3 contains conserved domains, including a YEATS domain that binds acetylated histones, facilitating transcriptional elongation. Beyond leukemia, MLLT3 contributes to normal hematopoiesis and stem cell maintenance. Studies highlight its role in embryonic development, neural differentiation, and cancer metastasis. The MLLT3 antibody is widely used in research to detect protein expression, localization, and interactions via techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). It aids in investigating MLL-rearranged leukemias, epigenetic dysregulation, and mechanisms of therapy resistance. Validated for specificity in human and murine models, this antibody remains essential for unraveling MLLT3's dual roles in oncogenesis and cellular homeostasis.